{
  "id": "602598201cb411341a0000af",
  "type": "factoid",
  "question": "What does bDMARD stand for?",
  "ideal_answer": "bDMARDs are biologic disease-modifying antirheumatic drugs.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30876919",
    "http://www.ncbi.nlm.nih.gov/pubmed/29980576",
    "http://www.ncbi.nlm.nih.gov/pubmed/32370139",
    "http://www.ncbi.nlm.nih.gov/pubmed/31058442",
    "http://www.ncbi.nlm.nih.gov/pubmed/31816434",
    "http://www.ncbi.nlm.nih.gov/pubmed/28412711",
    "http://www.ncbi.nlm.nih.gov/pubmed/24741293",
    "http://www.ncbi.nlm.nih.gov/pubmed/26404390",
    "http://www.ncbi.nlm.nih.gov/pubmed/31171315",
    "http://www.ncbi.nlm.nih.gov/pubmed/30799358",
    "http://www.ncbi.nlm.nih.gov/pubmed/29649840",
    "http://www.ncbi.nlm.nih.gov/pubmed/32494334"
  ],
  "snippets": [
    {
      "text": "Biologic disease-modifying antirheumatic drugs (bDMARDs) used for rheumatoid arthritis (RA) treatment have several mechanisms of action. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31058442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the present study we evaluated how systemic arterial hypertension (SAH), dyslipidemia and diabetes mellitus influence the efficacy, safety and retention rate of biological disease-modifying anti-rheumatic drug (bDMARD) treatment in rheumatic musculoskeletal disorders (RMDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32370139",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The introduction of biological disease-modifying antirheumatic drug (bDMARD) treatments for various types of autoimmune arthritis, such as rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis, represents a new era of treatment for patients with a refractory response to conventional synthetic DMARDs (csDMARDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30876919",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To establish in a global setting the relationships between countries' socioeconomic status (SES), measured biological disease modifying antirheumatic drug (bDMARD)-usage and disease outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29980576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biologic disease-modifying antirheumatic drugs (bDMARDs) are engineered proteins with high affinity for various proinflammatory immune mediators to reduce inflammation and its sequelae in various rheumatic diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31171315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are used in pregnant patients with rheumatic diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31816434",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of various non-infectious uveitis entities.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29649840",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412711",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Indeed, worldwide clinical trials of TNF inhibiting biologic disease modifying antirheumatic drugs (bDMARDs) including infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept as well as the humanized anti-human IL-6 receptor antibody, tocilizumab, have demonstrated outstanding clinical efficacy and tolerable safety profiles, resulting in worldwide approval for using these bDMARDs to treat moderate to severe active RA in patients with an inadequate response to synthetic disease modifying antirheumatic drugs (sDMARDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24741293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and tofacitinib, a targeted sDMARD, can be used to treat RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26404390",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32494334",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Objective Biological disease-modifying anti-rheumatic drugs (bDMARDs) represent an important advance in alleviating rheumatoid arthritis (RA), but their effect on rheumatic airway disease (AD) and interstitial lung disease (ILD) is still unclear.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30799358",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "biologic disease-modifying antirheumatic drugs"
}